Gene Patents Declared Invalid, For Now

Well, Judge Sweet has done what many had feared (hoped?) and teed up the gene patenting case for the Federal Circuit.  In a 156 page opinion issued yesterday, he ruled that, as a matter of law, the patents directed to “isolated DNA” are directed to non-patentable subject matter and are invalid under 35 U.S.C. § 101.  Similarly, claims related to methods of “comparing” or “analyzing” DNA sequences are abstract ideas and are likewise unpatentable under § 101.

Regarding the “isolated DNA” claims, the court ruled as follows:

[T]he clear line of Supreme Court precedent and accompanying lower court authorities . . . establishes that purification of a product of nature, without more, cannot transform it into patentable subject matter.  Rather, the purified product must possess “markedly different characteristics” in order to satisfy the requirement of § 101.

The court rejected all of Myriad’s arguments that isolated DNA is indeed markedly different from native DNA in the body and thus invalidated the isolated DNA claims.

For the method claims, the court relied on Bilski‘s machine-or-transformation test to invalidate the claims.  The court dismissed many of Myriad’s arguments regarding the transformative nature of the claims by holding that they were merely data gathering steps. 

The court did struggle a bit more with the claim directed to comparing the growth rate of cells in the presence or absence of a potential cancer therapeutic, but ultimately concluded that it was likewise invalid.

The court did dismiss the plaintiffs’ constitutional claims against the PTO and also did not rule on the constitutional claims against Myriad, citing the doctrine of constitutional avoidance.  When a court can rule on a statutory issue to provide the desired relief, it should refrain from ruling on a related constitutional issue.

The court recognizes that this decision will not stop the PTO from issuing claims of similar ilk to isolated DNA and methods of analyzing and comparing the DNA.  It seems to believe, however, that it will be affirmed by the Federal Circuit and perhaps the Supreme Court thus putting an end to these “evil” patents.

Make no mistake about it.  The ACLU only got involved in this case because it expects to take it to the Supreme Court.  The first step, however, is the Federal Circuit.  I agree with Patently-O and others that suggest the case will be reversed by the Federal Circuit and set up a potentially epic battle at the Supreme Court that could have enormous consequences to the biotechnology industry in the US.  As far as Federal Circuit review, this decision flies in the face of too many of that court’s and its predecessor’s precendents.  The Supreme Court is a bit more of a wild card.

About these ads

5 Responses to “Gene Patents Declared Invalid, For Now”

  1. Plaintiffs Begin Appellate Fight Over Gene Patents « INVENTIVE STEP Says:

    [...] Begin Appellate Fight Over Gene Patents By Matt Osenga As expected, Myriad has appealed the ruling by Judge Sweet that its patents on isolated genes and associated methods were invalid as not directed to [...]

  2. Justice Department Files Brief Arguing that Isolated Genes are Not Patentable « INVENTIVE STEP Says:

    [...] Arguing that Isolated Genes are Not Patentable By Matt Osenga In March, Judge Robert Sweet invalidated a number of patent claims directed to isolated gene sequences and methods of comparing o….  This case is now on appeal at the Federal Circuit.  The consensus is that the case will be [...]

  3. Amendments to America Invents Act « INVENTIVE STEP Says:

    [...] infringe a patent that relates to genetic diagnostic testing, obviously directed toward the Myriad case.  If the district court got the case right, why would this defense be [...]

  4. Federal Circuit Reverses District Court in Gene Patent Case « INVENTIVE STEP Says:

    [...] expected, the Federal Circuit reversed the district court’s determination that Myriad’s gene patents are not patentable, Association for Molecular Pathology v. Myriad [...]

  5. Supreme Court to Review Myriad Case Again « INVENTIVE STEP Says:

    [...] of the First Amendment to the Constitution.  In early 2010, the district court agreed that the gene patent claims were invalid under § 101 of the Patent Act, but not under the First [...]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Follow

Get every new post delivered to your Inbox.

Join 56 other followers

%d bloggers like this: